Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy

Next Previous
Trial Profile

A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ampreloxetine (Primary)
  • Indications Multiple system atrophy
  • Focus Registrational; Therapeutic Use
  • Acronyms CYPRESS
  • Sponsors Theravance Biopharma

Most Recent Events

  • 28 Apr 2025 According to a Theravance Biopharma media release, the data from this study will be presented at the International MSA Congress, taking place May 9-11, 2025, in Boston, Massachusetts.
  • 26 Feb 2025 According to a Theravance Biopharma media release, company is On track to enroll the final patient in the open label portion of the CYPRESS in mid-2025, with top-line data anticipated to be available approximately six months later.
  • 12 Nov 2024 According to a Theravance Biopharma media release, the corporate presentation under the Investors section, Events and Presentations, shows that CYPRESS is designed to reproduce study 0170 MSA patient results. A positive outcome of this trial, supported by Study 0170 data, are expected to be sufficient for regulatory filing.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top